Lantheus
LNTH
Collegium Pharmaceutical
COLL
Constellation Brands
STZ
4
Halozyme Therapeutics
HALO
5
AIRPORTS OF THAILAND PUBLIC CO UNSP ADR EACH REP 10 ORD SHS
AIPUY
(Q3)Dec 31, 2013 | (Q2)Sep 30, 2013 | (Q1)Jun 30, 2013 | (FY)Mar 31, 2013 | (Q4)Mar 31, 2013 | (Q3)Dec 31, 2012 | (Q2)Sep 30, 2012 | (Q1)Jun 30, 2012 | (FY)Mar 31, 2012 | (Q4)Mar 31, 2012 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | 44.41%-10.73K | 7.12%-37.98K | -15.90%-17.21K | 66.06%-100.98K | 33.81%-25.94K | 73.35%-19.29K | 75.83%-40.9K | 11.06%-14.85K | -31.41%-297.49K | -183.43%-39.2K |
Net income from continuing operations | -0.34%-16.04K | 15.30%-24.76K | -7.54%-27.39K | 64.57%-103.72K | 38.74%-33.04K | ---15.99K | ---29.23K | ---25.46K | ---292.72K | ---53.93K |
Change In working capital | 330.49%5.32K | -18.41%-13.23K | -24.97%10.18K | 136.54%2.17K | 117.29%2.08K | 92.86%-2.31K | -126.04%-11.17K | 400.75%13.56K | 84.32%-5.94K | -1,083.91%-12.04K |
-Change in prepaid assets | -57.06%1.44K | 58.89%-763 | 38.49%-2.05K | --0 | 32.02%1.84K | -71.67%3.34K | 86.52%-1.86K | -700.18%-3.33K | -147.62%-10 | 151.53%1.4K |
-Change in payables and accrued expense | 168.65%3.88K | -33.82%-12.47K | -27.64%12.23K | 136.60%2.17K | 101.78%239 | 87.18%-5.65K | -116.44%-9.32K | 433.56%16.9K | 84.35%-5.93K | -2,108.82%-13.44K |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | 44.41%-10.73K | 7.12%-37.98K | -15.90%-17.21K | 66.06%-100.98K | 33.81%-25.94K | 73.35%-19.29K | 75.83%-40.9K | 11.06%-14.85K | -31.41%-297.49K | -183.43%-39.2K |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 0 | 0 | 0 | 86.11%-5K | 75.00%-5K | 0 | 0 | 0 | -20.00%-36K | 33.33%-20K |
Net PPE purchase and sale | ---- | ---- | ---- | 75.00%-5K | ---- | ---- | ---- | ---- | 33.33%-20K | 33.33%-20K |
Net other investing changes | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---16K | --0 |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | --0 | --0 | --0 | 86.11%-5K | 75.00%-5K | --0 | --0 | --0 | -20.00%-36K | 33.33%-20K |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -40.00%300K | 0 |
Net issuance payments of debt | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --0 | --0 |
Net common stock issuance | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -40.00%300K | --0 |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | -40.00%300K | --0 |
Net cash flow | ||||||||||
Beginning cash position | -58.06%76.15K | -48.70%114.13K | -44.66%131.34K | -12.37%237.31K | -45.27%162.28K | 163.51%181.57K | -6.57%222.47K | -12.37%237.31K | 896.00%270.8K | -5.76%296.51K |
Current changes in cash | 44.41%-10.73K | 7.12%-37.98K | -15.90%-17.21K | -216.44%-105.98K | 47.73%-30.94K | -108.48%-19.29K | 75.83%-40.9K | 54.59%-14.85K | -113.75%-33.49K | -35.06%-59.2K |
End cash Position | -59.69%65.42K | -58.06%76.15K | -48.70%114.13K | -44.66%131.34K | -44.66%131.34K | -45.27%162.28K | 163.51%181.57K | -6.57%222.47K | -12.37%237.31K | -12.37%237.31K |
Free cash flow | 44.41%-10.73K | 7.12%-37.98K | -15.90%-17.21K | 66.62%-105.98K | 47.73%-30.94K | 73.35%-19.29K | 75.83%-40.9K | 11.06%-14.85K | -23.83%-317.49K | -35.06%-59.2K |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |